Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 12/20 | 0.78 |
| ▸ | PGK1 | P00558 | 3/20 | 0.65 |
| ▸ | PGK2 | P07205 | 3/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.63 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.63 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | THPO | P40225 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6913464 | 1.00 | ADORA2A (0.78) | ADORA2APGK1PGK2ADORA3ADORA1 | |
| SCHEMBL6327867 | 1.00 | ADORA2A (0.78) | ADORA2APGK1PGK2ADORA3ADORA1 | |
| SCHEMBL6913460 | 1.00 | ADORA2A (0.78) | ADORA2APGK1PGK2ADORA3ADORA1 | |
| SCHEMBL4560532 | 0.91 | ADORA2A (0.80) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL4373572 | 0.91 | ADORA2A (0.80) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL4373570 | 0.91 | ADORA2A (0.80) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL6326890 | 0.91 | ADORA2A (0.74) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL6052019 | 0.91 | ADORA2A (0.74) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL6347121 | 0.91 | ADORA2A (0.74) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL6347124 | 0.91 | ADORA2A (0.74) | ADORA2AADORA3ADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050250730-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-11-10 | — | — | US | claimed |
| US-20050209185-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-09-22 | — | — | US | claimed |
| US-6900309-B1 | Purine derivatives | PFIZER INC (US) | 2005-05-31 | — | — | US | claimed |
| US-20030013675-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-01-16 | — | — | US | claimed |
| US-20050250730-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-11-10 | — | — | US | disclosed |
| US-20050209185-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-09-22 | — | — | US | disclosed |
| US-20050124574-A1 | Purine derivatives | PFIZER INC. | 2005-06-09 | — | — | US | disclosed |
| US-6900309-B1 | Purine derivatives | PFIZER INC (US) | 2005-05-31 | — | — | US | disclosed |
| US-20030013675-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209185-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885PGK1 3439/4885PGK2 2859/4885 |
| US-20050124574-A1 | Purine derivatives | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885PGK1 1319/4885PGK2 1277/4885 |
| US-20030013675-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885PGK1 3376/4885PGK2 2135/4885 |
| US-20050250730-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885PGK1 3439/4885PGK2 2859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.